A bioinformatical and functional approach to identify novel strategies for chemoprevention of colorectal cancer

Oncogene

Volumn 30, Issue 17, 2011, Pages 2026-2036

  Heijink, D M ^a   Fehrmann, R S N ^a   De Vries, E G E ^a   Koornstra, J J ^a   Oosterhuis, D ^a   Van Der Zee, A G J ^a   Kleibeuker, J H ^a   De Jong, S ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

adenoma; chemoprevention; gene set enrichment; microarray; pathways

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; DASATINIB; FOLIC ACID; MESSENGER RNA; RETINOBLASTOMA PROTEIN; ROSCOVITINE; SONIC HEDGEHOG PROTEIN; WNT PROTEIN;

APOPTOSIS; ARTICLE; BIOINFORMATICS; BIOSYNTHESIS; CANCER PREVENTION; CELL CYCLE; CHEMOPROPHYLAXIS; COLON CARCINOGENESIS; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATIONAL STUDY; DATA BASE; DRUG TARGETING; GENE EXPRESSION; GENE ISOLATION; GENETIC ANALYSIS; GROWTH REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL;

ADENOMA; ARTIFACTS; CELL LINE, TUMOR; CHEMOPREVENTION; COLORECTAL NEOPLASMS; COMPUTATIONAL BIOLOGY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTESTINAL MUCOSA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS PP60(C-SRC); QUALITY CONTROL; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; RETINOBLASTOMA PROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

ERINACEIDAE;

EID: 79955469668     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.578     Document Type: Article

References (62)

1. Aldoss IT, Tashi T, Ganti AK. (2009). Seliciclib in malignancies. Expert Opin Invest Drugs 18: 1957-1965.
2. Alter O, Brown PO, Botstein D. (2000). Singular value decomposition for genome-wide expression data processing and modeling. Proc Natl Acad Sci USA 97: 10101-10106.
3. Arber N, Hibshoosh H, Moss SF, Sutter T, Zhang Y, Begg M et al. (1996). Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 110: 669-674. (Pubitemid 26071834)
4. Arber N, Levin B. (2008). Chemoprevention of colorectal neoplasia: the potential for personalized medicine. Gastroenterology 134: 1224-1237. (Pubitemid 351451998)
5. Arhel NJ, Packham G, Townsend PA, Collard TJ, Zadeh AM, Sharp A et al. (2003). The retinoblastoma protein interacts with Bag-1 in human colonic adenoma and carcinoma derived cell lines. Int J Cancer 106: 364-371. (Pubitemid 36870397)
6. Arima Y, Inoue Y, Shibata T, Hayashi H, Nagano O, Saya H et al. (2008). Rb depletion results in deregulation of E-cadherin and induction of cellular phenotypic changes that are characteristic of the epithelial-to-mesenchymal transition. Cancer Res 68: 5104-5112.
7. Bartkova J, Thullberg M, Slezak P, Jaramillo E, Rubio C, Thomassen LH. (2001). Aberrant expression of G1-phase cell cycle regulators in flat and exophytic adenomas of the human colon. Gastroenterology 120: 1680-1688. (Pubitemid 32523486)
8. Bild AH, Potti A, Nevins JR. (2006). Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer 6: 735-741. (Pubitemid 44304232)
9. Boquoi A, Chen T, Enders GH. (2009). Chemoprevention of mouse intestinal tumorigenesis by the cyclin-dependent kinase inhibitor SNS-032. Cancer Prev Res 2: 800-806.
10. Carey R, Jurickova I, Ballard E, Bonkowski E, Han X, Xu H et al. (2008). Activation of an IL-6:STAT3-dependent transcriptome in pediatric-onset inflammatory bowel disease. Inflamm Bowel Dis 14: 446-457. (Pubitemid 351571824)
11. Cartwright CA, Meisler AI, Eckhart W. (1990). Activation of the pp60c-Src protein kinase is an early event in colonic carcinogenesis. Proc Natl Acad Sci USA 87: 558-562.
12. Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ et al. (2009). Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 113: 4637-4645.
13. Chomczynski P, Sacchi N. (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159. (Pubitemid 17064313)
14. Cole AM, Myant K, Reed KR, Ridgway RA, Athineos D, van den Brink GR et al. (2010). Cyclin D2-cyclin-dependent kinase 4/6 is required for efficient proliferation and tumorigenesis following Apc loss. Cancer Res 70: 8149-8158.
15. Crijns AP, Fehrmann RS, de Jong S, Gerbens F, Meersma GJ, Klip HG et al. (2009). Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med 6: 181-193.
16. Crijns AP, Gerbens F, Plantinga AE, Meersma GJ, de Jong S, Hofstra RM et al. (2006). A biological question and a balanced (orthogonal) design: the ingredients to efficiently analyze two-color microarrays with confirmatory factor analysis. BMC Genomics 7: 232.
17. Dahlquist KD, Salomonis N, Vranizan K, Lawlor SC, Conklin BR. (2002). GenMAPP, a new tool for viewing and analyzing micro-array data on biological pathways. Nat Genet 31: 19-20.
18. de Hoon MJ, Imoto S, Nolan J, Miyano S. (2004). Open source clustering software. Bioinformatics 20: 1453-1454. (Pubitemid 38931415)
19. Du W, Searle JS. (2009). The rb pathway and cancer therapeutics. Curr Drug Targets 10: 581-589.
20. Edgar R, Domrachev M, Lash AE. (2002). Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207-210. (Pubitemid 34679544)
21. Einspahr JG, Martinez ME, Jiang R, Hsu CH, Rashid A, Bhatta-charrya AK et al. (2006). Associations of Ki-ras proto-oncogene mutation and p53 gene overexpression in sporadic colorectal adenomas with demographic and clinicopathologic characteristics. Cancer Epidemiol Biomarkers Prev 15: 1443-1450. (Pubitemid 44299313)
22. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade MA, Trachet E et al. (2004). Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3: 1428-1437.
23. Fujita T, Liu W, Doihara H, Wan Y. (2008). Regulation of Skp2-p27 axis by the Cdh1/anaphase-promoting complex pathway in color-ectal tumorigenesis. Am J Pathol 173: 217-228. (Pubitemid 351947969)
24. Galamb O, Gyorffy B, Sipos F, Spisak S, Nemeth AM, Miheller P et al. (2008). Inflammation, adenoma and cancer: objective classification of colon biopsy specimens with gene expression signature. Dis Markers 25: 1-16.
25. Giacinti C, Giordano A. (2006). RB and cell cycle progression. Oncogene 25: 5220-5227. (Pubitemid 44299080)
26. Guillen-Ahlers H, Buechler SA, Suckow MA, Castellino FJ, Ploplis VA. (2008). Sulindac treatment alters collagen and matrilysin expression in adenomas of ApcMin/+ mice. Carcinogen-esis 29: 1421-1427.
27. Hao X, Du M, Bishop AE, Talbot IC (1998). Imbalance between proliferation and apoptosis in the development of colorectal carcinoma. Virchows Arch 433: 523-527. (Pubitemid 28561184)
28. Hong Y, Ho KS, Eu KW, Cheah PY. (2007). A susceptibility gene set for early onset colorectal cancer that integrates diverse signaling path-ways: implication for tumorigenesis. Clin Cancer Res 13: 1107-1114. (Pubitemid 46424049)
29. Imazeki F, Yokosuka O, Yamaguchi T, Ohto M, Isono K, Omata M. (1996). Expression of variant CD44-messenger RNA in colorectal adenocarcinomas and adenomatous polyps in humans. Gastroenter-ology 110: 362-368. (Pubitemid 26043867)
30. Jalving M, de Jong S, Koornstra JJ, Boersma-van Ek W, Zwart N, Wesseling J et al. (2006). TRAIL induces apoptosis in human colorectal adenoma cell lines and human colorectal adenomas. Clin Cancer Res 12: 4350-4356.
31. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, Kawashima S et al. (2006). From genomics to chemical genomics: new developments in KEGG Nucleic Acids Res 34: 354-357.
32. Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S et al. (2007). Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 109: 5143-5150. (Pubitemid 46890528)
33. Kita H, Hikichi Y, Hikami K, Tsuneyama K, Cui ZG, Osawa H et al. (2006). Differential gene expression between flat adenoma and normal mucosa in the colon in a microarray analysis. J Gastroenterol 41: 1053-1063. (Pubitemid 44896720)
34. Knudsen ES, Wang JY. (2010). Targeting the RB-pathway in cancer therapy. Clin Cancer Res 16: 1094-1099.
35. Koornstra JJ, Rijcken FE, de Jong S, Hollema H, de Vries EG, Kleibeuker JH. (2004). Assessment of apoptosis by M30 immunor-eactivity and the correlation with morphological criteria in normal colorectal mucosa, adenomas and carcinomas. Histopathology 44: 9-17. (Pubitemid 38174864)
36. Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU et al. (2009). Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 69: 3842-3849.
37. Kwong LN, Weiss KR, Haigis KM, Dove WF. (2008). Atm is a negative regulator ofintestinal neoplasia. Oncogene 27: 1013-1018. (Pubitemid 351225386)
38. LaPointe LC, Dunne R, Brown GS, Worthley DL, Molloy PL, Wattchow D et al. (2008). Map of differential transcript expression in the normal human large intestine. Physiol Genomics 33: 50-64. (Pubitemid 351451374)
39. Li J, Rix U, Fang B, Bai Y, Edwards A, Colinge J et al. (2010). A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol 6: 291-299.
40. Lin YM, Furukawa Y, Tsunoda T, Yue CT, Yang KC, Nakamura Y. (2002). Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas. Oncogene 21: 4120-4128. (Pubitemid 34712879)
41. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS et al. (1996). Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 14: 1675-1680. (Pubitemid 26414810)
42. Michaud K, Solomon D, Oermann E, Kim J-S, Zhong W-Z, Prados MD et al. (2010). Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res 70: 3228-3238.
43. Midgley R, Kerr D. (1999). Colorectal cancer. Lancet 353: 391-399. (Pubitemid 29088178)
44. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J et al. (2003). PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34: 267-273. (Pubitemid 36792858)
45. Nielsen TO, West RB, Linn SC, Alter O, Knowling MA, O'Connell JX et al. (2002). Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 359: 1301-1307. (Pubitemid 34310636)
46. Paulson QX, Pusapati RV, Hong S, Weaks RL, Conti CJ, Johnson DG. (2008). Transgenic expression of E2F3a causes DNA damage leading to ATM-dependent apoptosis. Oncogene 27: 4954-4961.
47. Payne SR, Zhang S, Tsuchiya K, Moser R, Gurley KE, Longton G et al. (2008). p27kip1 deficiency impairs G2/M arrest in response to DNA damage, leading to an increase in genetic instability. Mol Cell Biol 28: 258-268.
48. Rencher A. (1998). Mutivariate Statistical Interference and Applications. John Wiley & Sons Inc.: New York, USA.
49. Sabates-Bellver J, van der Flier LG, de Palo M, Cattaneo E, Maake C, Rehrauer H et al. (2007). Transcriptome profile of human colorectal adenomas. Mol Cancer Res 5: 1263-1275.
50. Senderowicz AM. (2003). Small-molecule cyclin-dependent kinase modulators. Oncogene 22: 6609-6620. (Pubitemid 37372341)
51. Serrels A, Macpherson IR, Evans TR, Lee FY, Clark EA, Sansom OJ et al. (2006). Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther 5: 3014-3022. (Pubitemid 46092042)
52. Sherlock G (2001). Analysis of large-scale gene expression data. Brief Bioinform 2: 350-362.
53. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545-15550. (Pubitemid 41528093)
54. Timmerbeul I, Garrett-Engele CM, Kossatz U, Chen X, Firpo E, Grunwald V et al. (2006). Testing the importance of p27 degradation by the SCFskp2 pathway in murine models of lung and colon cancer. Proc Natl Acad Sci USA 103: 14009-14014. (Pubitemid 44452971)
55. van Geelen CM, de Vries EG, Le PT, van Weeghel RP, de Jong S. (2003). Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines. Br J Cancer 89: 363-373. (Pubitemid 36976328)
56. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M et al. (1988). Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525-532.
57. Vogelstein B, Kinzler KW. (2004). Cancer genes and the pathways they control. Nat Med 10: 789-799. (Pubitemid 39070849)
58. Wai PY, Mi Z, Gao C, Guo H, Marroquin C, Kuo PC (2006). Ets-1 and runx2 regulate transcription of a metastatic gene, osteopontin, in murine colorectal cancer cells. J Biol Chem 281: 18973-18982. (Pubitemid 44035400)
59. Wesierska-Gadek J, Maurer M, Zulehner N, Komina O. (2011). Whether to target single or multiple CDKs for therapy? That is the question. J Cell Physiol 226: 341-349.
60. Whittaker SR, Walton MI, Garrett MD, Workman P. (2004). The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res 64: 262-272. (Pubitemid 38114107)
61. Yeatman TJ. (2004). A renaissance for Src Nat Rev Cancer 4: 470-480. (Pubitemid 38745532)
62. Zhao P, Mao X, Talbot IC (2006). Aberrant cytological localization of p16 and CDK4 in colorectal epithelia in the normal adenoma carcinoma sequence. World J Gastroenterol 12: 6391-6396. (Pubitemid 44712426)